MEDICAL ENGINEERING TECHNOLOGY
LIN Xiaohui, ZHANG Shuxu, LIAO Yuliang, ZENG Qingxing, ZHANG Guoqian,YU Hui, LEI Huaiyu
Objective To explore the role and significance of independent dose accounting and dose reconstruction function of
Compass system in three-dimensional dose verification of intensity-modulated radiotherapy plan for nasopharyngeal carcinoma.
Methods Thirty patients with nasopharyngeal carcinoma were designed for intensive radiotherapy plan, and the dose distribution
calculated by the radiotherapy plan system (PD), the patient’s calculated dose distribution (CD) based on the built-in dose plan
model: collapsed cone convolution of Compass, the three-dimensional reconstructed dose distribution (RD) by Compass were
compared and analyzed in two ways (Group A: PD vs. CD; Group B: PD vs. RD; Group C: CD vs. RD). The Gamma passing rate,
D99%, Dmean, D1%, Dmean difference, Pmean of the target area and organs at risk were analyzed. Results In Group A, B and C, the average
Gamma passing rate of Globle were more than 97% (3 mm/3% standard), and the relative deviations of D1% and Dmean were less than
2.5%. The Gamma passing rate of globle, GTVnd, parotid, eye, len and temporal lobe in Group B was lower than that in Group
A, and the difference was statistically significant (P<0.05). The Gamma passing rate of globle, GTVnd, CTV1, CTV2, parotid, len
and temporal lobe in Group B was lower than that in Group C, and the difference was statistically significant (P<0.05). The relative
deviations of dose of the target area in Group A, B and C were mostly between 0.8% and 2.5%, and a small part was about 2.7% to
3.2%. The Dmean difference of GTVnd, GTVnx, CTV1, CTV2 and Globle in Group A was statistically significant (P<0.05), except
Optical chiasm, the Dmean difference of the other organs at risk in Group C was statistically significant (P<0.05). Conclusion The
combination of independent dose accounting and dose reconstruction work of Compass system can provide an effective means for
three-dimensional dose verification of clinical radiotherapy plans.